ArticleBMC infectious diseases2026
Prevalence and factors associated with drug resistance mutations among HIV - 1 patients failing to achieve virological suppression on second line treatment in Tanzania.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS) is a major public health problem affecting an estimated 38.4 million people globally, with 54% of them being from the Eastern and Southern African regions. Despite progress in the availability of multiple classes of antiretroviral drugs and early initiation of treatment with cART, many patients still fail to achieve viral suppression on first and second-line regimens due to drug resistance that is driven by continuous acquisition of drug resistance mutation (DRMs). DRMs are prevalent among adults failing treatment regimens, ranging between 50 and 97%. This study aimed to determine the prevalence and factors associated with drug resistance mutations among patients failing to achieve virologic suppression on second-line treatment in Tanzania. A facility-based analytical retrospective study was conducted at Temeke Hospital, Dar es Salaam, Tanzania. Data was extracted from medical records of 176 patients with viral load > 1000c/ml who underwent drug resistance testing during the period between February 2021 and July 2023. Data was analyzed using SPSS V26 and summarized using descriptive statistics. A multivariable logistic regression model was used to estimate the adjusted odds ratio with a 95% confidence interval for biodemographic factors associated with antiretroviral drug resistance mutations. We found high prevalence of DRMs at 71.1% (95% CI; 63.7–77.6) whereby NNRTI mutations were present in 69.3% (n = 122), NRTI in 52.8%(n = 93) and PI in 23.9% (n = 42) while 26.7%(n = 47) had triple class DRMs. Protease inhibitors had the lowest prevalence of DRMs while NNRTI was the highest. Older age [AOR = 1.037, 95% CI; (1.004–1.071)] and number of regimen changes [AOR = 1.479, 95% CI; (1.026–2.131)] were independently significantly associated with higher DRMs at p < 0.05. The prevalence of DRM is high. PI appear to have the least prevalence of DRM, followed NRTIs. This supports the utilization of PIs and selected NRTI in second- and third-line regimens as they less affected by DRMs. Closer monitoring is recommended for older patients and patients with multiple regimen changes as they are likely to harbour DRMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.